Actively Recruiting
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
Led by Wenjin Yin · Updated on 2025-11-18
123
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
CONDITIONS
Official Title
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female, age 18 years or older
- Expected survival of at least 12 weeks
- ECOG performance status of 0 or 1
- Pathologically confirmed recurrent or metastatic breast cancer not suitable for curative surgery
- Estrogen receptor and/or progesterone receptor positive, HER2 negative
- At least one measurable lesion or bone-only disease (osteolytic or mixed) based on RECIST v1.1
- Previously treated with two or fewer lines of chemotherapy for advanced disease
- Previously treated with two or fewer CDK4/6 inhibitors
- Adequate organ function
You will not qualify if you...
- Pregnant or breastfeeding
- Presence of central nervous system metastasis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China, 200127
Actively Recruiting
Research Team
W
Wenjin Yin, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here